- Conditions
- Cerebral Palsy, Muscle Spasticity, Children
- Interventions
- Botulinum toxin type A
- Biological
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 10,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Depressive Disorder, Major
- Interventions
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo
- Drug · Other
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 42
- States / cities
- Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
- Conditions
- Hemophilia A
- Interventions
- FVIII concentrate
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Lexington, Kentucky + 9 more
- Conditions
- Uncontrolled Hypertension
- Interventions
- Renal denervation (Symplicity Catheter System), Renal angiogram
- Device · Diagnostic Test
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 61 more
- Conditions
- Autism Spectrum Disorder, Developmental Disorder
- Interventions
- Not listed
- Lead sponsor
- Stemina Biomarker Discovery, Inc.
- Industry
- Eligibility
- 18 Months to 48 Months
- Enrollment
- 1,102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Sacramento, California + 5 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Frexalimab, Placebo, Insulin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
- Conditions
- Moderate-to-severe Chronic Noncancer Pain
- Interventions
- Oxycodone extended-release
- Drug
- Lead sponsor
- Egalet Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Jacksonville, Florida + 35 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Arcadia, California • Poway, California • Sacramento, California + 33 more
- Conditions
- Participants Undergoing Anthracycline Chemotherapy
- Interventions
- autoRIC®
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more
- Conditions
- Acne Vulgaris
- Interventions
- Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
- Drug · Other
- Lead sponsor
- Dermira, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 36
- States / cities
- Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more
- Conditions
- Hypertension
- Interventions
- LCZ696, Valsartan, AHU377, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
- Conditions
- Hypertension, Essential
- Interventions
- Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
- Conditions
- Narcolepsy Type 1
- Interventions
- ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 22
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Subcutaneous AKB-9778
- Drug
- Lead sponsor
- Aerpio Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Winter Haven, Florida • Baltimore, Maryland + 3 more
- Conditions
- Hypertension
- Interventions
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 50
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
- Conditions
- Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
- Interventions
- Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
- Drug · Device
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 24 Weeks to 27 Weeks
- Enrollment
- 1,316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more
- Conditions
- Colorectal Cancer
- Interventions
- Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 92
- States / cities
- Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
- Conditions
- Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 94
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
- Interventions
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Drug
- Lead sponsor
- Corvus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Duarte, California • San Francisco, California + 18 more
- Conditions
- Episodic Migraine
- Interventions
- Standard of Care (SOC) Migraine Preventive Medication, Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
- Conditions
- Prostate Cancer
- Interventions
- tarenflurbil, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more